|Use||Contraception, menopause, hypogonadism, transgender women, prostate cancer, breast cancer, others|
|Biological target||Estrogen receptors (ER?, ER?, mERs (e.g., GPER, others))|
Estrogen or oestrogen, is a category of sex hormone responsible for the development and regulation of the female reproductive system and secondary sex characteristics. There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3). Estradiol, an estrane, is the most potent and prevalent. Another estrogen called estetrol (E4) is produced only during pregnancy.
Estrogens are synthesized in all vertebrates and some insects. Their presence in both vertebrates and insects suggests that estrogenic sex hormones have an ancient evolutionary history. Quantitatively, estrogens circulate at lower levels than androgens in both men and women. While estrogen levels are significantly lower in males than in females, estrogens nevertheless have important physiological roles in males.
Like all steroid hormones, estrogens readily diffuse across the cell membrane. Once inside the cell, they bind to and activate estrogen receptors (ERs) which in turn modulate the expression of many genes. Additionally, estrogens bind to and activate rapid-signaling membrane estrogen receptors (mERs), such as GPER (GPR30).
In addition to their role as natural hormones, estrogens are used as medications, for instance in menopausal hormone therapy, hormonal birth control and feminizing hormone therapy for transgender women and nonbinary people.
Structures of major endogenous estrogens
The four major naturally occurring estrogens in women are estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4). Estradiol is the predominant estrogen during reproductive years both in terms of absolute serum levels as well as in terms of estrogenic activity. During menopause, estrone is the predominant circulating estrogen and during pregnancy estriol is the predominant circulating estrogen in terms of serum levels. Given by subcutaneous injection in mice, estradiol is about 10-fold more potent than estrone and about 100-fold more potent than estriol. Thus, estradiol is the most important estrogen in non-pregnant females who are between the menarche and menopause stages of life. However, during pregnancy this role shifts to estriol, and in postmenopausal women estrone becomes the primary form of estrogen in the body. Another type of estrogen called estetrol (E4) is produced only during pregnancy. All of the different forms of estrogen are synthesized from androgens, specifically testosterone and androstenedione, by the enzyme aromatase.
Minor endogenous estrogens, the biosyntheses of which do not involve aromatase, include 27-hydroxycholesterol, dehydroepiandrosterone (DHEA), 7-oxo-DHEA, 7?-hydroxy-DHEA, 16?-hydroxy-DHEA, 7?-hydroxyepiandrosterone, androstenedione (A4), androstenediol (A5), 3?-androstanediol, and 3?-androstanediol. Some estrogen metabolites, such as the catechol estrogens 2-hydroxyestradiol, 2-hydroxyestrone, 4-hydroxyestradiol, and 4-hydroxyestrone, as well as 16?-hydroxyestrone, are also estrogens with varying degrees of activity. The biological importance of these minor estrogens is not entirely clear.
The actions of estrogen are mediated by the estrogen receptor (ER), a dimeric nuclear protein that binds to DNA and controls gene expression. Like other steroid hormones, estrogen enters passively into the cell where it binds to and activates the estrogen receptor. The estrogen:ER complex binds to specific DNA sequences called a hormone response element to activate the transcription of target genes (in a study using an estrogen-dependent breast cancer cell line as model, 89 such genes were identified). Since estrogen enters all cells, its actions are dependent on the presence of the ER in the cell. The ER is expressed in specific tissues including the ovary, uterus and breast. The metabolic effects of estrogen in postmenopausal women have been linked to the genetic polymorphism of the ER.
While estrogens are present in both men and women, they are usually present at significantly higher levels in women of reproductive age. They promote the development of female secondary sexual characteristics, such as breasts, and are also involved in the thickening of the endometrium and other aspects of regulating the menstrual cycle. In males, estrogen regulates certain functions of the reproductive system important to the maturation of sperm and may be necessary for a healthy libido.
|Ligand||Other names||Relative binding affinities (RBA, %)a||Absolute binding affinities (Ki, nM)a||Action|
|Estradiol||E2; 17?-Estradiol||100||100||0.115 (0.04-0.24)||0.15 (0.10-2.08)||Estrogen|
|Estrone||E1; 17-Ketoestradiol||16.39 (0.7-60)||6.5 (1.36-52)||0.445 (0.3-1.01)||1.75 (0.35-9.24)||Estrogen|
|Estriol||E3; 16?-OH-17?-E2||12.65 (4.03-56)||26 (14.0-44.6)||0.45 (0.35-1.4)||0.7 (0.63-0.7)||Estrogen|
|Alfatradiol||17?-Estradiol||20.5 (7-80.1)||8.195 (2-42)||0.2-0.52||0.43-1.2||Metabolite|
|Estradiol sulfate||E2S; Estradiol 3-sulfate||<1||<1||?||?||Metabolite|
|Estradiol disulfate||Estradiol 3,17?-disulfate||0.0004||?||?||?||Metabolite|
|Estradiol 3-gluc. 17?-sulfate||E2-3G-17S||0.0001||?||?||?||Metabolite|
|Estrone sulfate||E1S; Estrone 3-sulfate||<1||<1||>10||>10||Metabolite|
|Estradiol benzoate||EB; Estradiol 3-benzoate||10||?||?||?||Estrogen|
|Estrone methyl ether||Estrone 3-methyl ether||0.145||?||?||?||Estrogen|
|Ethinylestradiol||EE; 17?-Ethynyl-17?-E2||120.9 (68.8-480)||44.4 (2.0-144)||0.02-0.05||0.29-0.81||Estrogen|
|Mestranol||EE 3-methyl ether||?||2.5||?||?||Estrogen|
|Diethylstilbestrol||DES; Stilbestrol||129.5 (89.1-468)||219.63 (61.2-295)||0.04||0.05||Estrogen|
|Tamoxifen||ICI-46,474||3 (0.1-47)||3.33 (0.28-6)||3.4-9.69||2.5||SERM|
|Afimoxifene||4-Hydroxytamoxifen; 4-OHT||100.1 (1.7-257)||10 (0.98-339)||2.3 (0.1-3.61)||0.04-4.8||SERM|
|Raloxifene||-||41.2 (7.8-69)||5.34 (0.54-16)||0.188-0.52||20.2||SERM|
|Fulvestrant||ICI-182,780||43.5 (9.4-325)||21.65 (2.05-40.5)||0.42||1.3||Antiestrogen|
|Propylpyrazoletriol||PPT||49 (10.0-89.1)||0.12||0.40||92.8||ER? agonist|
|Prinaberel||ERB-041; WAY-202,041||0.27||67-72||?||?||ER? agonist|
|Erteberel||SERBA-1; LY-500,307||?||?||2.68||0.19||ER? agonist|
|Coumestrol||-||9.225 (0.0117-94)||64.125 (0.41-185)||0.14-80.0||0.07-27.0||Xenoestrogen|
|Genistein||-||0.445 (0.0012-16)||33.42 (0.86-87)||2.6-126||0.3-12.8||Xenoestrogen|
|Daidzein||-||0.07 (0.0018-9.3)||0.7865 (0.04-17.1)||2.0||85.3||Xenoestrogen|
|Biochanin A||-||0.04 (0.022-0.15)||0.6225 (0.010-1.2)||174||8.9||Xenoestrogen|
|Kaempferol||-||0.07 (0.029-0.10)||2.2 (0.002-3.00)||?||?||Xenoestrogen|
|Naringenin||-||0.0054 (<0.001-0.01)||0.15 (0.11-0.33)||?||?||Xenoestrogen|
|Zearalenone||ZEN||7.68 (2.04-28)||9.45 (2.43-31.5)||?||?||Xenoestrogen|
|Bisphenol A||BPA||0.0315 (0.008-1.0)||0.135 (0.002-4.23)||195||35||Xenoestrogen|
|Dihydrotestosterone||DHT; 5?-Androstanolone||0.01 (<0.001-0.05)||0.0059-0.17||221->5000||73-1688||Androgen|
|Dehydroepiandrosterone||DHEA; Prasterone||0.038 (<0.001-0.04)||0.019-0.07||245-1053||163-515||Androgen|
|Norethisterone||NET; 17?-Ethynyl-19-NT||0.085 (0.0015-<0.1)||0.1 (0.01-0.3)||152||1084||Progestogen|
|Footnotes: a = (1) Binding affinity values are of the format "median (range)" (# (#-#)), "range" (#-#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety of in-vitro systems with labeled estradiol and human ER? and ER? proteins (except the ER? values from Kuiper et al. (1997), which are rat ER?). Sources: See template page.|
|Estrogen||Relative binding affinities (%)|
|Notes: Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, dexamethasone for the GR, aldosterone for the MR, dihydrotestosterone for SHBG, and cortisol for CBG. Sources: See template.|
|Estrogen||Other names||RBA (%)a||REP (%)b|
|Estradiol 3-sulfate||E2S; E2-3S||?||0.02||0.04|
|Estradiol benzoate||EB; Estradiol 3-benzoate||10||1.1||0.52|
|Estradiol diacetate||EDA; Estradiol 3,17?-diacetate||?||0.79||?|
|Estradiol propionate||EP; Estradiol 17?-propionate||19-26||2.6||?|
|Estradiol valerate||EV; Estradiol 17?-valerate||2-11||0.04-21||?|
|Estradiol cypionate||EC; Estradiol 17?-cypionate||?c||4.0||?|
|Estradiol palmitate||Estradiol 17?-palmitate||0||?||?|
|Estradiol stearate||Estradiol 17?-stearate||0||?||?|
|Estrone sulfate||E1S; Estrone 3-sulfate||2||0.004||0.002|
|Estrone glucuronide||E1G; Estrone 3-glucuronide||?||<0.001||0.0006|
|Mestranol||EE 3-methyl ether||1||1.3-8.2||0.16|
|Quinestrol||EE 3-cyclopentyl ether||?||0.37||?|
|Footnotes: a = Relative binding affinities (RBAs) were determined via in-vitro displacement of labeled estradiol from estrogen receptors (ERs) generally of rodent uterine cytosol. Estrogen esters are variably hydrolyzed into estrogens in these systems (shorter ester chain length -> greater rate of hydrolysis) and the ER RBAs of the esters decrease strongly when hydrolysis is prevented. b = Relative estrogenic potencies (REPs) were calculated from half-maximal effective concentrations (EC50) that were determined via in-vitro ?-galactosidase (?-gal) and green fluorescent protein (GFP) production assays in yeast expressing human ER? and human ER?. Both mammalian cells and yeast have the capacity to hydrolyze estrogen esters. c = The affinities of estradiol cypionate for the ERs are similar to those of estradiol valerate and estradiol benzoate (figure). Sources: See template page.|
|Estrogen||ER RBA (%)||Uterine weight (%)||Uterotrophy||LH levels (%)||SHBG RBA (%)|
|Estradiol||100||506 ± 20||+++||12-19||100|
|Estrone||11 ± 8||490 ± 22||+++||?||20|
|Estriol||10 ± 4||468 ± 30||+++||8-18||3|
|Estetrol||0.5 ± 0.2||?||Inactive||?||1|
|17?-Estradiol||4.2 ± 0.8||?||?||?||?|
|2-Hydroxyestradiol||24 ± 7||285 ± 8||+b||31-61||28|
|2-Methoxyestradiol||0.05 ± 0.04||101||Inactive||?||130|
|4-Hydroxyestradiol||45 ± 12||?||?||?||?|
|4-Methoxyestradiol||1.3 ± 0.2||260||++||?||9|
|4-Fluoroestradiola||180 ± 43||?||+++||?||?|
|2-Hydroxyestrone||1.9 ± 0.8||130 ± 9||Inactive||110-142||8|
|2-Methoxyestrone||0.01 ± 0.00||103 ± 7||Inactive||95-100||120|
|4-Hydroxyestrone||11 ± 4||351||++||21-50||35|
|4-Methoxyestrone||0.13 ± 0.04||338||++||65-92||12|
|16?-Hydroxyestrone||2.8 ± 1.0||552 ± 42||+++||7-24||<0.5|
|2-Hydroxyestriol||0.9 ± 0.3||302||+b||?||?|
|2-Methoxyestriol||0.01 ± 0.00||?||Inactive||?||4|
|Notes: Values are mean ± SD or range. ER RBA = Relative binding affinity to estrogen receptors of rat uterine cytosol. Uterine weight = Percentage change in uterine wet weight of ovariectomized rats after 72 hours with continuous administration of 1 ?g/hour via subcutaneously implanted osmotic pumps. LH levels = Luteinizing hormone levels relative to baseline of ovariectomized rats after 24 to 72 hours of continuous administration via subcutaneous implant. Footnotes: a = Synthetic (i.e., not endogenous). b = Atypical uterotrophic effect which plateaus within 48 hours (estradiol's uterotrophy continues linearly up to 72 hours). Sources: See template.|
Estrogens are responsible for the development of female secondary sexual characteristics during puberty, including breast development, widening of the hips, and female fat distribution. Conversely, androgens are responsible for pubic and body hair growth, as well as acne and axillary odor.
Estrogen, in conjunction with growth hormone (GH) and its secretory product insulin-like growth factor 1 (IGF-1), is critical in mediating breast development during puberty, as well as breast maturation during pregnancy in preparation of lactation and breastfeeding. Estrogen is primarily and directly responsible for inducing the ductal component of breast development, as well as for causing fat deposition and connective tissue growth. It is also indirectly involved in the lobuloalveolar component, by increasing progesterone receptor expression in the breasts and by inducing the secretion of prolactin. Allowed for by estrogen, progesterone and prolactin work together to complete lobuloalveolar development during pregnancy.
Estrogens are responsible for maturation and maintenance of the vagina and uterus, and are also involved in ovarian function, such as maturation of ovarian follicles. In addition, estrogens play an important role in regulation of gonadotropin secretion. For these reasons, estrogens are required for female fertility.
Estrogen regulated DNA repair mechanisms in the brain have neuroprotective effects. Estrogen regulates the transcription of DNA base excision repair genes as well as the translocation of the base excision repair enzymes between different subcellular compartments.
Estrogens are involved in libido (sex drive) in both women and men.
Verbal memory scores are frequently used as one measure of higher level cognition. These scores vary in direct proportion to estrogen levels throughout the menstrual cycle, pregnancy, and menopause. Furthermore, estrogens when administered shortly after natural or surgical menopause prevents decreases in verbal memory. In contrast, estrogens have little effect on verbal memory if first administered years after menopause. Estrogens also have positive influences on other measures of cognitive function. However the effect of estrogens on cognition is not uniformly favorable and is dependent on the timing of the dose and the type of cognitive skill being measured.
The protective effects of estrogens on cognition may be mediated by estrogen's anti-inflammatory effects in the brain. Studies have also shown that the Met allele gene and level of estrogen mediates the efficiency of prefrontal cortex dependent working memory tasks. Researchers have urged for further research to illuminate the role of estrogen and its potential for improvement on cognitive function.
Estrogen is considered to play a significant role in women's mental health. Sudden estrogen withdrawal, fluctuating estrogen, and periods of sustained low estrogen levels correlate with significant mood lowering. Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of estrogen were stabilized and/or restored. Menstrual exacerbation (including menstrual psychosis) is typically triggered by low estrogen levels, and is often mistaken for premenstrual dysphoric disorder.
Compulsions in male lab mice, such as those in obsessive-compulsive disorder (OCD), may be caused by low estrogen levels. When estrogen levels were raised through the increased activity of the enzyme aromatase in male lab mice, OCD rituals were dramatically decreased. Hypothalamic protein levels in the gene COMT are enhanced by increasing estrogen levels which are believed to return mice that displayed OCD rituals to normal activity. Aromatase deficiency is ultimately suspected which is involved in the synthesis of estrogen in humans and has therapeutic implications in humans having obsessive-compulsive disorder.
Local application of estrogen in the rat hippocampus has been shown to inhibit the re-uptake of serotonin. Contrarily, local application of estrogen has been shown to block the ability of fluvoxamine to slow serotonin clearance, suggesting that the same pathways which are involved in SSRI efficacy may also be affected by components of local estrogen signaling pathways.
Studies have also found that fathers had lower levels of cortisol and testosterone but higher levels of estrogen (estradiol) than did non-fathers.
Estrogen may play a role in suppressing binge eating. Hormone replacement therapy using estrogen may be a possible treatment for binge eating behaviors in females. Estrogen replacement has been shown to suppress binge eating behaviors in female mice. The mechanism by which estrogen replacement inhibits binge-like eating involves the replacement of serotonin (5-HT) neurons. Women exhibiting binge eating behaviors are found to have increased brain uptake of neuron 5-HT, and therefore less of the neurotransmitter serotonin in the cerebrospinal fluid. Estrogen works to activate 5-HT neurons, leading to suppression of binge like eating behaviors.
It is also suggested that there is an interaction between hormone levels and eating at different points in the female menstrual cycle. Research has predicted increased emotional eating during hormonal flux, which is characterized by high progesterone and estradiol levels that occur during the mid-luteal phase. It is hypothesized that these changes occur due to brain changes across the menstrual cycle that are likely a genomic effect of hormones. These effects produce menstrual cycle changes, which result in hormone release leading to behavioral changes, notably binge and emotional eating. These occur especially prominently among women who are genetically vulnerable to binge eating phenotypes.
Binge eating is associated with decreased estradiol and increased progesterone. Klump et al. Progesterone may moderate the effects of low estradiol (such as during dysregulated eating behavior), but that this may only be true in women who have had clinically diagnosed binge episodes (BEs). Dysregulated eating is more strongly associated with such ovarian hormones in women with BEs than in women without BEs.
The implantation of 17?-estradiol pellets in ovariectomized mice significantly reduced binge eating behaviors and injections of GLP-1 in ovariectomized mice decreased binge-eating behaviors.
In rodents, estrogens (which are locally aromatized from androgens in the brain) play an important role in psychosexual differentiation, for example, by masculinizing territorial behavior; the same is not true in humans. In humans, the masculinizing effects of prenatal androgens on behavior (and other tissues, with the possible exception of effects on bone) appear to act exclusively through the androgen receptor. Consequently, the utility of rodent models for studying human psychosexual differentiation has been questioned.
Estrogens are responsible for both the pubertal growth spurt, which causes an acceleration in linear growth, and epiphyseal closure, which limits height and limb length, in both females and males. In addition, estrogens are responsible for bone maturation and maintenance of bone mineral density throughout life. Due to hypoestrogenism, the risk of osteoporosis increases during menopause.
Women suffer less from heart disease due to vasculo-protective action of estrogen which helps in preventing atherosclerosis. It also helps in maintaining the delicate balance between fighting infections and protecting arteries from damage thus lowering the risk of cardiovascular disease. During pregnancy, high levels of estrogens increase coagulation and the risk of venous thromboembolism.
|Absolute incidence of first VTE per 10,000 person-years during pregnancy and the postpartum period|
|Swedish data A||Swedish data B||English data||Danish data|
|Time period||N||Rate (95% CI)||N||Rate (95% CI)||N||Rate (95% CI)||N||Rate (95% CI)|
|Outside pregnancy||1105||4.2 (4.0-4.4)||1015||3.8 (?)||1480||3.2 (3.0-3.3)||2895||3.6 (3.4-3.7)|
|Antepartum||995||20.5 (19.2-21.8)||690||14.2 (13.2-15.3)||156||9.9 (8.5-11.6)||491||10.7 (9.7-11.6)|
|Trimester 1||207||13.6 (11.8-15.5)||172||11.3 (9.7-13.1)||23||4.6 (3.1-7.0)||61||4.1 (3.2-5.2)|
|Trimester 2||275||17.4 (15.4-19.6)||178||11.2 (9.7-13.0)||30||5.8 (4.1-8.3)||75||5.7 (4.6-7.2)|
|Trimester 3||513||29.2 (26.8-31.9)||340||19.4 (17.4-21.6)||103||18.2 (15.0-22.1)||355||19.7 (17.7-21.9)|
|Around delivery||115||154.6 (128.8-185.6)||79||106.1 (85.1-132.3)||34||142.8 (102.0-199.8)|
|Postpartum||649||42.3 (39.2-45.7)||509||33.1 (30.4-36.1)||135||27.4 (23.1-32.4)||218||17.5 (15.3-20.0)|
|Early postpartum||584||75.4 (69.6-81.8)||460||59.3 (54.1-65.0)||177||46.8 (39.1-56.1)||199||30.4 (26.4-35.0)|
|Late postpartum||65||8.5 (7.0-10.9)||49||6.4 (4.9-8.5)||18||7.3 (4.6-11.6)||319||3.2 (1.9-5.0)|
|Incidence rate ratios (IRRs) of first VTE during pregnancy and the postpartum period|
|Swedish data A||Swedish data B||English data||Danish data|
|Time period||IRR* (95% CI)||IRR* (95% CI)||IRR (95% CI)+||IRR (95% CI)+|
Reference (i.e., 1.00)
|Antepartum||5.08 (4.66-5.54)||3.80 (3.44-4.19)||3.10 (2.63-3.66)||2.95 (2.68-3.25)|
|Trimester 1||3.42 (2.95-3.98)||3.04 (2.58-3.56)||1.46 (0.96-2.20)||1.12 (0.86-1.45)|
|Trimester 2||4.31 (3.78-4.93)||3.01 (2.56-3.53)||1.82 (1.27-2.62)||1.58 (1.24-1.99)|
|Trimester 3||7.14 (6.43-7.94)||5.12 (4.53-5.80)||5.69 (4.66-6.95)||5.48 (4.89-6.12)|
|Around delivery||37.5 (30.9-44.45)||27.97 (22.24-35.17)||44.5 (31.68-62.54)|
|Postpartum||10.21 (9.27-11.25)||8.72 (7.83-9.70)||8.54 (7.16-10.19)||4.85 (4.21-5.57)|
|Early postpartum||19.27 (16.53-20.21)||15.62 (14.00-17.45)||14.61 (12.10-17.67)||8.44 (7.27-9.75)|
|Late postpartum||2.06 (1.60-2.64)||1.69 (1.26-2.25)||2.29 (1.44-3.65)||0.89 (0.53-1.39)|
|Notes: Swedish data A = Using any code for VTE regardless of confirmation. Swedish data B = Using only algorithm-confirmed VTE. Early postpartum = First 6 weeks after delivery. Late postpartum = More than 6 weeks after delivery. * = Adjusted for age and calendar year. + = Unadjusted ratio calculated based on the data provided. Source: |
Estrogens are implicated in various estrogen-dependent conditions, such as ER-positive breast cancer, as well as a number of genetic conditions involving estrogen signaling or metabolism, such as estrogen insensitivity syndrome, aromatase deficiency, and aromatase excess syndrome.
Estrogens, in females, are produced primarily by the ovaries, and during pregnancy, the placenta. Follicle-stimulating hormone (FSH) stimulates the ovarian production of estrogens by the granulosa cells of the ovarian follicles and corpora lutea. Some estrogens are also produced in smaller amounts by other tissues such as the liver, pancreas, bone, adrenal glands, skin, brain, adipose tissue, and the breasts. These secondary sources of estrogens are especially important in postmenopausal women. The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues and the level of aromatase.
In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak androgenic activity which serves predominantly as a precursor for more potent androgens such as testosterone as well as estrogen. This compound crosses the basal membrane into the surrounding granulosa cells, where it is converted either immediately into estrone, or into testosterone and then estradiol in an additional step. The conversion of androstenedione to testosterone is catalyzed by 17?-hydroxysteroid dehydrogenase (17?-HSD), whereas the conversion of androstenedione and testosterone into estrone and estradiol, respectively is catalyzed by aromatase, enzymes which are both expressed in granulosa cells. In contrast, granulosa cells lack 17?-hydroxylase and 17,20-lyase, whereas theca cells express these enzymes and 17?-HSD but lack aromatase. Hence, both granulosa and theca cells are essential for the production of estrogen in the ovaries.
Note that in males, estrogen is also produced by the Sertoli cells when FSH binds to their FSH receptors.
|Reference range (serum levels)|
|SI units||Non-SI units|
|2.8 mg/day||1.6 mg/day||2200 L/day||2.8-7.3 nmol/L||80-210 ng/dL|
|6.5 mg/day||6.2 mg/day||950 L/day||6.9-34.7 nmol/L||200-1000 ng/dL|
|150 ?g/day||110 ?g/day||2050 L/day||37-250 pmol/L||10-70 pg/mL|
|60 ?g/day||50 ?g/day||1600 L/day||<37-210 pmol/L||10-57 pg/mL|
|80 ?g/day||Insignificant||167 L/day||600-2500 pmol/L||200-900 pg/mL|
|3.2 mg/day||2.8 mg/day||2000 L/day||3.1-12.2 nmol/L||89-350 ng/dL|
|190 ?g/day||60 ?g/day||500 L/day||0.7-2.8 nmol/L||20-81 ng/dL|
|Estrone||Follicular phase||110 ?g/day||80 ?g/day||2200 L/day||110-400 pmol/L||30-110 pg/mL|
|Luteal phase||260 ?g/day||150 ?g/day||2200 L/day||310-660 pmol/L||80-180 pg/mL|
|Postmenopause||40 ?g/day||Insignificant||1610 L/day||22-230 pmol/L||6-60 pg/mL|
|Estradiol||Follicular phase||90 ?g/day||80 ?g/day||1200 L/day||<37-360 pmol/L||10-98 pg/mL|
|Luteal phase||250 ?g/day||240 ?g/day||1200 L/day||699-1250 pmol/L||190-341 pg/mL|
|Postmenopause||6 ?g/day||Insignificant||910 L/day||<37-140 pmol/L||10-38 pg/mL|
|Estrone sulfate||Follicular phase||100 ?g/day||Insignificant||146 L/day||700-3600 pmol/L||250-1300 pg/mL|
|Luteal phase||180 ?g/day||Insignificant||146 L/day||1100-7300 pmol/L||400-2600 pg/mL|
|Progesterone||Follicular phase||2 mg/day||1.7 mg/day||2100 L/day||0.3-3 nmol/L||0.1-0.9 ng/mL|
|Luteal phase||25 mg/day||24 mg/day||2100 L/day||19-45 nmol/L||6-14 ng/mL|
Estrogens are metabolized via hydroxylation by cytochrome P450 enzymes such as CYP1A1 and CYP3A4 and via conjugation by estrogen sulfotransferases (sulfation) and UDP-glucuronyltransferases (glucuronidation). In addition, estradiol is dehydrogenated by 17?-hydroxysteroid dehydrogenase into the much less potent estrogen estrone. These reactions occur primarily in the liver, but also in other tissues.
Estrogen metabolism in humans
Estrogens are used as medications, mainly in hormonal contraception, hormone replacement therapy, and to treat gender dysphoria in transgender women and other transfeminine individuals as part of feminizing hormone therapy.
In 1929, Adolf Butenandt and Edward Adelbert Doisy independently isolated and purified estrone, the first estrogen to be discovered. Then, estriol and estradiol were discovered in 1930 and 1933, respectively. Shortly following their discovery, estrogens, both natural and synthetic, were introduced for medical use. Examples include estriol glucuronide (Emmenin, Progynon), estradiol benzoate, conjugated estrogens (Premarin), diethylstilbestrol, and ethinylestradiol.
The word estrogen derives from Ancient Greek. It is derived from "oestros" (a periodic state of sexual activity in female mammals), and genos (generating). It was first published in the early 1920s and referenced as "oestrin". With the years, American English adapted the spelling of estrogen to fit with its phonetic pronunciation. Nevertheless, both estrogen and oestrogen are used nowadays, yet some still wish to maintain its original spelling as it reflects the origin of the word.
Estrogens are among the wide range of endocrine-disrupting compounds (EDCs) because they have high estrogenic potency. When an EDC makes its way into the environment, it may cause male reproductive dysfunction to wildlife. The estrogen excreted from farm animals makes its way into fresh water systems. During the germination period of reproduction the fish are exposed to low levels of estrogen which may cause reproductive dysfunction to male fish.
Some hair shampoos on the market include estrogens and placental extracts; others contain phytoestrogens. In 1998, there were case reports of four prepubescent African-American girls developing breasts after exposure to these shampoos. In 1993, the FDA determined that not all over-the-counter topically applied hormone-containing drug products for human use are generally recognized as safe and effective and are misbranded. An accompanying proposed rule deals with cosmetics, concluding that any use of natural estrogens in a cosmetic product makes the product an unapproved new drug and that any cosmetic using the term "hormone" in the text of its labeling or in its ingredient statement makes an implied drug claim, subjecting such a product to regulatory action.
In addition to being considered misbranded drugs, products claiming to contain placental extract may also be deemed to be misbranded cosmetics if the extract has been prepared from placentas from which the hormones and other biologically active substances have been removed and the extracted substance consists principally of protein. The FDA recommends that this substance be identified by a name other than "placental extract" and describing its composition more accurately because consumers associate the name "placental extract" with a therapeutic use of some biological activity.